Eli Lilly and Company (NYSE: LLY) stock traded around $1,030.23, up 0.66%, during Thursday’s session as investors assessed the drugmaker’s latest U.S. manufacturing expansion.
Eli Lilly and Company, LLY
The pharmaceutical giant announced plans to build a $3.5 billion injectable drug facility in Pennsylvania, reinforcing its push to scale domestic production while meeting soaring demand for weight-loss therapies.
The new site will be Lilly’s fourth U.S. manufacturing plant announced as part of its broader “Lilly in America” initiative. The company is expanding capacity as competition intensifies in the GLP-1 market and as policy pressure grows to localize pharmaceutical supply chains in the United States.
We’re investing $3.5 billion in a new U.S. facility in the Lehigh Valley, Pennsylvania—the final site in our recent U.S. manufacturing commitments. The project is expected to bring 2,850 manufacturing and construction jobs to the region. Learn more: https://t.co/PTF9VS0oTN… pic.twitter.com/TAI0VNIyez
— Eli Lilly and Company (@EliLillyandCo) January 30, 2026
The Pennsylvania facility will be located in the Lehigh Valley region, specifically in Fogelsville, after Lilly reviewed more than 300 potential locations nationwide. Construction is expected to begin in 2026, with the plant becoming operational in 2031. Once complete, the site will focus on injectable medicines and device manufacturing, with a strong emphasis on next-generation obesity treatments.
The $3.5 billion investment represents the largest life sciences manufacturing commitment in Pennsylvania history. State officials said the project will create at least 850 permanent jobs across engineering, scientific research, manufacturing operations, and laboratory roles, while also supporting thousands of indirect construction and supply-chain positions.
Lilly said the new plant will manufacture injectable weight-loss medicines, including retatrutide, its experimental triple hormone receptor agonist. Retatrutide has shown strong clinical performance and has outpaced the company’s blockbuster obesity drug Zepbound in trials, positioning it as a potential next wave therapy in the fast-growing weight-loss market.
The company continues to race Danish rival Novo Nordisk to meet global demand for GLP-1 drugs, which has strained supply chains across the industry. Lilly also plans to launch an oral weight-loss pill internationally at a cash price of about $150 per month as it works toward U.S. regulatory approval in the coming months.
Lilly’s U.S. investment push comes as President Donald Trump has threatened to impose tariffs on imported pharmaceutical products. Drugmakers including Lilly, Pfizer, and Merck have pledged billions toward domestic manufacturing to reduce exposure to potential trade penalties.
Since 2020, Lilly has committed more than $50 billion to U.S. manufacturing expansions. The four plants announced over the past year alone account for more than $27 billion in pledged investment, underscoring a structural shift toward localized drug production.
Lilly said the Pennsylvania plant will deploy advanced technologies such as artificial intelligence, machine learning, integrated monitoring systems, and data analytics to improve manufacturing efficiency and quality control. The company also plans to partner with local universities and invest in education programs across Pennsylvania to develop a skilled workforce pipeline.
The Lehigh Valley location was selected for its proximity to STEM universities, established technical manufacturing base, and existing infrastructure. Once a hub of heavy industry, the region has become a focal point for advanced manufacturing redevelopment.
The Pennsylvania site follows several major Lilly manufacturing announcements over the past year. The company is building a $6 billion active pharmaceutical ingredient facility in Huntsville, Alabama, focused on peptide and small-molecule drugs, including oral GLP-1 candidate orforglipron. Another $6.5 billion plant in Houston will support cardiometabolic, oncology, immunology, and neuroscience drugs, while a $5 billion facility in Virginia will focus on monoclonal antibodies and bioconjugates.
Lilly’s long-term stock performance remains strong. The shares are up more than 26% over the past year and over 420% across five years, far outpacing the S&P 500. While the stock is down modestly year-to-date, investors continue to view Lilly as a cornerstone name in the obesity and cardiometabolic drug space.
The Pennsylvania expansion reinforces Lilly’s strategy to secure supply, defend market leadership, and align manufacturing with long-term growth in next-generation weight-loss therapies.
The post Eli Lilly And Company (LLY) Stock: Shares Hold Firm As $3.5B U.S. Manufacturing Expansion Accelerates appeared first on CoinCentral.
